Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
Personalis presented clinical data at ASCO 2026 demonstrating the NeXT Personal MRD test achieved 100% sensitivity for colorectal cancer recurrence during surveillance and 82% sensitivity just four weeks post-surgery. The company also highlighted ultrasensitive performance in lung cancer, detecting ctDNA at a median limit of 1.66 ppm, with patients showing sub-10 ppm levels facing a 3-fold increased risk of recurrence.
Key figures
- Melanoma patients
- 98
- Crc study patients
- over 100
- Nsclc median lod ppm
- 1.66
- Nsclc study patients
- 431
- Ovarian cancer patients
- 72
- Endometrial cancer patients
- 99
- Rcc baseline detection rate
- 84%
- Crc sensitivity surveillance
- 100%
- Melanoma recurrence lead days
- 212
- Crc sensitivity 4wks post surgery
- 82%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.